[go: up one dir, main page]

EA200600479A1 - Фармацевтический состав, включающий соединения лантана - Google Patents

Фармацевтический состав, включающий соединения лантана

Info

Publication number
EA200600479A1
EA200600479A1 EA200600479A EA200600479A EA200600479A1 EA 200600479 A1 EA200600479 A1 EA 200600479A1 EA 200600479 A EA200600479 A EA 200600479A EA 200600479 A EA200600479 A EA 200600479A EA 200600479 A1 EA200600479 A1 EA 200600479A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lanthanum
compounds
mixture
pressing
effective amount
Prior art date
Application number
EA200600479A
Other languages
English (en)
Other versions
EA012798B1 (ru
Inventor
Жозефин Кристин Фердинандо
Роберт Пол Хаслам
Лаура Анна Треспиди
Original Assignee
Шир Холдингз Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34221462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200600479(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шир Холдингз Аг filed Critical Шир Холдингз Аг
Publication of EA200600479A1 publication Critical patent/EA200600479A1/ru
Publication of EA012798B1 publication Critical patent/EA012798B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к жевательному составу, содержащему лантан, включающему фармацевтически эффективное количество соединения лантана; и по меньшей мере один жевательный фармацевтически приемлемый наполнитель. Изобретение относится также к фармацевтическому составу в форме таблетки или порошка, содержащего фармацевтически эффективное количество соединения лантана, приготовленного согласно способу, включающему этапы: а) смешивания порошковых форм соединения лантана и по меньшей мере одного фармацевтически приемлемого наполнителя в смесителе с получением смеси; или b) смешивания порошковых форм соединения лантана и вспомогательных веществ, прессования образовавшейся комбинации в агрегированный материал или прессования в вальцах образовавшейся комбинации с получением материала в виде ленты, измельчения изготовленного материала в свободно текущую смесь; и с) таблетирования образовавшейся смеси или наполнения образовавшейся смесью соответствующего контейнера.
EA200600479A 2003-08-26 2004-08-26 Фармацевтический состав, содержащий карбонат лантана (варианты) EA012798B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49756003P 2003-08-26 2003-08-26
US51707803P 2003-11-05 2003-11-05
PCT/CA2004/001563 WO2005018651A1 (en) 2003-08-26 2004-08-26 Pharmaceutical formulation comprising lanthanum compounds

Publications (2)

Publication Number Publication Date
EA200600479A1 true EA200600479A1 (ru) 2006-08-25
EA012798B1 EA012798B1 (ru) 2009-12-30

Family

ID=34221462

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200600479A EA012798B1 (ru) 2003-08-26 2004-08-26 Фармацевтический состав, содержащий карбонат лантана (варианты)
EA200970709A EA200970709A1 (ru) 2003-08-26 2004-08-26 Фармацевтический состав, содержащий соединения лантана

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200970709A EA200970709A1 (ru) 2003-08-26 2004-08-26 Фармацевтический состав, содержащий соединения лантана

Country Status (28)

Country Link
US (2) US7465465B2 (ru)
EP (4) EP2133084B1 (ru)
JP (2) JP4896719B2 (ru)
KR (1) KR100830764B1 (ru)
CN (1) CN1871018B (ru)
AT (2) ATE460169T1 (ru)
AU (2) AU2004266050B2 (ru)
BR (1) BRPI0413394A8 (ru)
CA (1) CA2536959C (ru)
CY (2) CY1110241T1 (ru)
CZ (1) CZ17621U1 (ru)
DE (2) DE202004021169U1 (ru)
DK (5) DK1660104T3 (ru)
EA (2) EA012798B1 (ru)
ES (4) ES2592803T3 (ru)
FI (1) FI7568U1 (ru)
HU (2) HUE024906T2 (ru)
IL (2) IL173755A0 (ru)
IS (1) IS2893B (ru)
MX (1) MXPA06002257A (ru)
NO (1) NO342559B1 (ru)
NZ (1) NZ545633A (ru)
PL (4) PL1660104T3 (ru)
PT (4) PT2172205E (ru)
SG (1) SG145765A1 (ru)
SI (4) SI2172205T1 (ru)
WO (1) WO2005018651A1 (ru)
ZA (1) ZA200602213B (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
RU2296584C2 (ru) * 2001-04-23 2007-04-10 Шир Интернешнл Лайсенсин Б.В. Применение соединений редкоземельных металлов для предотвращения мочекаменной болезни
US20060083791A1 (en) * 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
CA2536959C (en) * 2003-08-26 2011-08-02 Shire Holdings Ag Pharmaceutical formulation comprising lanthanum compounds
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
MX2007001114A (es) * 2004-07-27 2007-07-11 Shire Pharmaceuticals Inc Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano.
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
CA2583548A1 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
ITME20040015A1 (it) 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
EP1698233A1 (en) * 2005-03-01 2006-09-06 Bayer HealthCare AG Reduction of digestibility of phosphorus in animal nutrition
DE06801934T1 (de) * 2005-08-17 2009-01-15 Altairnano, Inc., Reno Hyperphosphatämie bei haustieren: zusammensetzungen und verfahren zur behandlung
US20080058250A1 (en) * 2005-08-17 2008-03-06 Allison Wren Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
CN100398112C (zh) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 一种治疗血磷酸盐过多症的药物及其制备方法
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
RU2471356C2 (ru) * 2007-07-31 2013-01-10 Карджилл, Инкорпорейтед Декстроза для прямого прессования
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
TWI592159B (zh) 2007-11-16 2017-07-21 威佛（國際）股份有限公司 藥學組成物
WO2009118760A2 (en) * 2008-03-26 2009-10-01 Matrix Laboratories Limited Lanthanum composition
ES2433076T3 (es) * 2009-01-21 2013-12-09 Mylan Inc. Formulaciones disgregables de carbonato de lantano
WO2010106557A2 (en) * 2009-03-20 2010-09-23 Panacea Biotec Limited Stable pharmaceutical formulations comprising anhydrous lanthanum carbonate and process for preparation thereof
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
AU2010313075A1 (en) * 2009-10-26 2012-05-31 Alkem Laboratories Ltd. Pharmaceutical compositions of lanthanum carbonate and process for the preparation thereof
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
AU2011252983C1 (en) 2010-05-12 2015-02-19 Unicycive Therapeutics, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
EP2441436A1 (de) 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Phosphatbinderformulierung zur einfachen Einnahme
US8263119B2 (en) 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
CN103127041A (zh) * 2012-02-23 2013-06-05 南京卡文迪许生物工程技术有限公司 含有醋酸镧的药物组合物及其制备方法和用途
DE102012209411A1 (de) 2012-06-04 2013-12-05 Fim Biotech Gmbh Mineralische Verbindung zur Reduzierung von anorganischen Phosphaten, insbesondere im Rahmen einer Nierenersatztherapie
CN104473963B (zh) * 2014-12-24 2017-10-10 厦门科明达科技有限公司 稀土化学药碳酸镧咀嚼片的制备方法
JP2016147827A (ja) * 2015-02-12 2016-08-18 株式会社三和化学研究所 炭酸ランタン水和物を含有する医薬製剤
US10058569B2 (en) 2015-06-24 2018-08-28 Lupin Limited Lanthanum carbonate compositions
JP6093829B1 (ja) * 2015-10-02 2017-03-08 バイエル薬品株式会社 ランタン化合物を含む医薬組成物
JP6623753B2 (ja) * 2015-12-28 2019-12-25 ニプロ株式会社 炭酸ランタンを含む口腔内崩壊錠
CN107213126B (zh) * 2017-05-17 2020-06-23 西安棣加生物科技有限公司 一种3d打印技术制备治疗高磷血症的口腔速崩片的方法
CN108969497A (zh) * 2018-10-12 2018-12-11 沈阳华泰药物研究有限公司 一种碳酸镧片剂组合物及其制备方法
WO2021101461A1 (en) 2019-11-21 2021-05-27 Santa Farma İlaç Sanayi̇ A.Ş. Oral solid pharmaceutical compositions comprising lanthanum carbonate octahydrate
CN113244179B (zh) * 2021-05-21 2023-01-13 浙江仟源海力生制药有限公司 一种稳定性好的碳酸镧片剂及其制备方法和其应用
US20230123099A1 (en) * 2021-10-15 2023-04-20 Fertin Pharma A/S Dextrose tablets with improved mouthfeel
CN115813867B (zh) * 2022-12-01 2024-05-24 山东齐都药业有限公司 碳酸镧冻干片及其制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54155675A (en) * 1978-05-30 1979-12-07 Matsushita Electronics Corp Small-sized fluorescent lamp
JPH06705B2 (ja) 1985-12-19 1994-01-05 旭化成工業株式会社 リン酸イオンの固定化剤
US4822594A (en) 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4877735A (en) 1987-06-19 1989-10-31 Takeda Chemical Industries, Ltd. Process for producing 2-keto-L-gulonic acid
JPS6485088A (en) 1987-06-19 1989-03-30 Takeda Chemical Industries Ltd Production of 2-keto-l-gulonic acid
DE3724188C2 (de) 1987-07-17 1995-05-18 Heinz Dr Gries Metallhaltige Oligosaccharid-Polysulfate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
ES2096103T3 (es) * 1992-01-13 1997-03-01 Pfizer Preparacion de comprimidos de resistencia incrementada.
DK0760648T3 (da) 1994-05-20 2002-02-25 Janssen Pharmaceutica Nv Flubendazoltyggetabletter til kæledyr
US5562921A (en) * 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
JP3591886B2 (ja) 1994-09-05 2004-11-24 シーシーアイ株式会社 希土類元素集積微生物
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6074672A (en) 1996-06-28 2000-06-13 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Powdered cosmetic compositions containing silicone elastomers
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
GB9816899D0 (en) * 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
US6270790B1 (en) * 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
JP2000173537A (ja) * 1998-09-29 2000-06-23 Toshiba Lighting & Technology Corp 低圧水銀蒸気放電灯および照明装置
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0008392D0 (en) 2000-04-05 2000-05-24 Unilever Plc Process for the production of a deodorant or antiperspirant product
GB0015745D0 (en) 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
US20020057059A1 (en) * 2000-07-28 2002-05-16 Kazuhisa Ogishi Fluorescent lamp, self-ballasted fluorescent lamp and lighting apparatus
JP2002047210A (ja) 2000-08-04 2002-02-12 Nihon Medi Physics Co Ltd 尿路結石防止用組成物
US7090875B2 (en) 2000-12-19 2006-08-15 Kabushiki Kaisha Yakult Honsha External skin preparations and process for producing the same
JP4612180B2 (ja) 2000-12-19 2011-01-12 株式会社ヤクルト本社 皮膚外用剤
JP4612183B2 (ja) 2000-12-27 2011-01-12 株式会社ヤクルト本社 皮膚外用組成物及びその製造方法
US20020122823A1 (en) 2000-12-29 2002-09-05 Bunick Frank J. Soft tablet containing dextrose monohydrate
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
RU2296584C2 (ru) * 2001-04-23 2007-04-10 Шир Интернешнл Лайсенсин Б.В. Применение соединений редкоземельных металлов для предотвращения мочекаменной болезни
GB0201607D0 (en) 2002-01-24 2002-03-13 Gamlen Michael J D Formulation for the administration of medicinal substances
EP1499300B1 (en) * 2002-04-29 2009-03-18 Supernus Pharmaceuticals, Inc. Pharmaceutical formulations with improved bioavailability
WO2003094933A2 (en) * 2002-05-08 2003-11-20 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US7220406B2 (en) 2002-10-22 2007-05-22 Genzyme Corporation Method for promoting bone formation
CA2536959C (en) 2003-08-26 2011-08-02 Shire Holdings Ag Pharmaceutical formulation comprising lanthanum compounds
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7545784B2 (en) * 2004-02-11 2009-06-09 Yahoo! Inc. System and method for wireless communication between previously known and unknown users
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
CA2557848C (en) 2004-03-30 2013-12-10 Ilypsa, Inc. Ion binding compositions
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
MX2007001114A (es) * 2004-07-27 2007-07-11 Shire Pharmaceuticals Inc Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano.
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
WO2009118760A2 (en) 2008-03-26 2009-10-01 Matrix Laboratories Limited Lanthanum composition

Also Published As

Publication number Publication date
ES2478258T3 (es) 2014-07-21
IL235371B (en) 2018-08-30
ES2592803T3 (es) 2016-12-01
AU2009202429B2 (en) 2012-03-22
IS2893B (is) 2014-09-15
CN1871018A (zh) 2006-11-29
IS8353A (is) 2006-03-15
CN1871018B (zh) 2011-11-02
DE602004025950D1 (de) 2010-04-22
CA2536959A1 (en) 2005-03-03
EP2792363B1 (en) 2016-06-29
CY1110241T1 (el) 2015-01-14
HK1084338A1 (en) 2006-07-28
ES2532389T3 (es) 2015-03-26
BRPI0413394A8 (pt) 2016-03-08
NO20061347L (no) 2006-05-15
EP1660104A4 (en) 2006-10-18
PT2172205E (pt) 2014-07-17
CY1118211T1 (el) 2017-06-28
PL2172205T3 (pl) 2015-01-30
EP2133084A2 (en) 2009-12-16
EP2172205A1 (en) 2010-04-07
DK2133084T3 (en) 2015-04-13
EP2172205B1 (en) 2014-06-18
PT1660104E (pt) 2010-06-15
JP2010248247A (ja) 2010-11-04
DE202004021169U1 (de) 2007-03-01
PT2792363T (pt) 2016-09-26
DK2792363T3 (da) 2016-09-26
US20050079135A1 (en) 2005-04-14
PT2133084E (pt) 2015-04-16
KR100830764B1 (ko) 2008-05-20
PL2133084T3 (pl) 2015-08-31
NO342559B1 (no) 2018-06-18
EP1660104B1 (en) 2010-03-10
SI2172205T1 (sl) 2014-10-30
SI1660104T1 (sl) 2010-08-31
HUE024906T2 (en) 2016-02-29
EA200970709A1 (ru) 2010-04-30
US7465465B2 (en) 2008-12-16
EP2792363A1 (en) 2014-10-22
JP4896719B2 (ja) 2012-03-14
NZ545633A (en) 2009-07-31
PL1660104T3 (pl) 2010-08-31
EP2133084B1 (en) 2015-02-18
JP2007503400A (ja) 2007-02-22
FI7568U1 (fi) 2007-07-17
EP2133084A3 (en) 2010-02-03
MXPA06002257A (es) 2006-05-17
EP1660104A1 (en) 2006-05-31
WO2005018651A1 (en) 2005-03-03
EA012798B1 (ru) 2009-12-30
DK2172205T3 (da) 2014-07-14
CZ17621U1 (cs) 2007-06-25
AU2004266050B2 (en) 2009-06-18
DK1660104T3 (da) 2010-06-21
AT9809U1 (de) 2008-04-15
ATE460169T1 (de) 2010-03-15
CA2536959C (en) 2011-08-02
ES2343354T3 (es) 2010-07-29
KR20060118420A (ko) 2006-11-23
BRPI0413394A (pt) 2006-10-17
DK200600252U1 (da) 2007-01-12
SI2133084T1 (sl) 2015-07-31
AU2009202429A1 (en) 2009-07-09
SG145765A1 (en) 2008-09-29
FIU20060387U0 (fi) 2006-09-22
US20090017133A1 (en) 2009-01-15
IL173755A0 (en) 2006-07-05
HUE029382T2 (en) 2017-02-28
ZA200602213B (en) 2009-04-29
SI2792363T1 (sl) 2016-11-30
PL2792363T3 (pl) 2017-01-31
DK200600252U4 (da) 2007-11-23
AU2004266050A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
EA200600479A1 (ru) Фармацевтический состав, включающий соединения лантана
CL2010001275A1 (es) Metodo para producir un producto intermedio compactado de bibw 2992 ma2 que comprende una etapa de compactacion por rodillos de bibw 2992 ma2 u opcionalmente en una premezcla con 0-1,0% de lubricante en un mezclador de caida libre o de volteo y una etapa de tamizado; producto intermedio compactado; comprimido.
RU2004118709A (ru) Составы, содержащие азитромицин, поддающиеся прямому прессованию
DE69902046D1 (de) Neue feste dosisform enthaltend nanopartikelnaproxen
CA2294337A1 (en) Preparation of pharmaceutical compositions
ZA200410109B (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability.
MXPA05012191A (es) Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos.
DE60008374D1 (de) Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten
GEP20033062B (en) Pharmaceutical Composition Comprising Entacapone or Nitecapone and Cross-Linked Cellulose Derivative
WO2002024203A3 (en) Controlled release formulations for oral administration
PL382307A1 (pl) Sposób przygotowania farmaceutycznej kompozycji w postaci szybko dyspersyjnej dawki i stała, doustna, szybko dyspersyjna postać dawki
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
WO2007120838A3 (en) Rapidly disintegrating solid oral dosage form of liquid dispersions
AU2001263892A1 (en) Device for storing and mixing pasty materials
ES2171110A1 (es) Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion.
AU9124401A (en) Stabilization of solid thyroid drug formulations
WO2003013441A3 (en) Levothyroxine compositions and methods
WO2005037192A3 (en) Ibuprofen narcotic composition and method for making same
WO2005094893A3 (en) Freeze-dried, free-flowing, particulate composition having improved palatability
CA2532714A1 (en) Oral sustained-release tablet comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide
CA2406592A1 (en) Method of preparing pharmaceutical dosage forms containing multiple active ingredients
CY1115392T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν ενωσεις λανθανιου
BRPI0418769A (pt) composição farmacêutica compreendendo cefixima, processo para a preparação de uma forma de dosagem oral sólida compreendendo de partìculas de cefixima, método para conseguir bio-equivalência entre a forma de dosagem oral e uma suspensão e comprimido mastigável compreendendo cefixima
ATE350031T1 (de) Synergistische leberschützende zusammensetzung und verfahren dazu
TH80550A (th) ยาผสมตามสูตรชนิดอัดโดยตรง และกระบวนการ

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM